alliqua inc (ALQA:OTC US)

Executive Profile*

Background*

Dr. Jerome Bernard Zeldis, Jerry, M.D., Ph.D. serves as the Chief Medical Officer, Senior Vice President of Clinical Research and Medical Development and Vice President of Medical Affairs at Celgene Corporation. Dr. Zeldis serves as the Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation. He has been employed at Celgene Corporation since 1997. He has extensive drug development experience gained through his career at Celgene, ... Inc. He served as Assistant Professor of Medicine at the Harvard Medical School from July 1987 to September 1988, Associate Professor of Medicine at University of California, Davis from September 1988 to September 1994, Clinical Associate Professor of Medicine at Cornell Medical School from January 1995 to December 2003 and Professor of Clinical Medicine at the Robert Wood Johnson Medical School from July 1998 to June 2010. Dr. Zeldis served as an Associate Director of clinical research and Director of medical development at Sandoz Research Institute and Janssen Pharmaceutical Research Institute. From September 1994 to February 1997, he worked at Sandoz Research Institute and the Janssen Research Institute in both clinical research and medical development. He is an experienced global industry leader with a distinguished career at one of the world's leading biopharmaceutical companies with operations in more than 50 countries and products sold in more than 70 markets in the Americas, Europe, and Asia Pacific regions. He has been the Chairman of Alliqua, Inc. since November 29, 2012. Dr. Zeldis serves as a Director of Semorex Inc. (also known as Semorex Corporation) and Celgene Cellular Therapeutics (also known as Anthrogenesis Corporation). He has been a Director of IR Biosciences Holdings Inc. since November 1, 2007 and Soligenix, Inc. since June 22, 2011. He has been a Director of PTC Therapeutics, Inc. since September 28, 2012 and Alliqua, Inc. since May 17, 2012. He serves as a Director of ImmuneRegen BioSciences, Inc. He serves on the board of the NJ Chapter of the Arthritis Foundation and the Castleman's Disease Organization. He has been a Director of Bionor Pharma ASA since April 11, 2012. He has published 116 peer reviewed articles and 24 reviews, book chapters, and editorials. He completed an trained in internal medicine at the UCLA Center for the Health Sciences and was a clinical and gastroenterology at Massachusetts General Hospital and Harvard Medical School. Dr. Zeldis holds an BA and an M Sc. in Molecular Biology from Brown University and a M. Phil, a MD and a PhD in Molecular Biophysics and Biochemistry from Yale University.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
ALQA:US	$0.07 USD	+0.0058

COMPETITOR COMPENSATION